Literature DB >> 27164718

Fingolimod-associated PML in a patient with prior immunosuppression.

Tirisham V Gyang1, Johanna Hamel2, Andrew D Goodman2, Robert A Gross2, Lawrence Samkoff2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27164718      PMCID： PMC4862251          DOI： 10.1212/WNL.0000000000002654

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.

Authors:  G Francis; L Kappos; P O'Connor; W Collins; D Tang; F Mercier; J A Cohen
Journal:  Mult Scler       Date:  2013-08-15       Impact factor: 6.312

3.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 4.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

5.  Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Daniel Pelletier; Diego Cadavid; Achim Gass; Nancy D Richert; Ernst-Wilhelm Radue; Massimo Filippi
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

6.  Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.

Authors:  Rocco Totaro; Caterina Di Carmine; Gianfranco Costantino; Roberta Fantozzi; Paolo Bellantonio; Aurora Fuiani; Ciro Mundi; Stefano Ruggieri; Carmine Marini; Antonio Carolei
Journal:  Mult Scler Int       Date:  2015-07-22
  6 in total
  19 in total

1.  Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

Authors:  Luca Prosperini; Cristina Scarpazza; Luisa Imberti; Cinzia Cordioli; Nicola De Rossi; Ruggero Capra
Journal:  J Neurovirol       Date:  2017-08-08       Impact factor: 2.643

Review 2.  [MRI alterations in immunomodulation].

Authors:  K Guggenberger; H Urbach
Journal:  Nervenarzt       Date:  2018-08       Impact factor: 1.214

3.  Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy.

Authors:  Susanta Mondal; Suresh B Rangasamy; Supurna Ghosh; Richard L Watson; Kalipada Pahan
Journal:  Neurochem Res       Date:  2017-03-07       Impact factor: 3.996

Review 4.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

Review 5.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 6.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

7.  Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Authors:  Shinji Aoyama; Masahiro Mori; Akiyuki Uzawa; Tomohiko Uchida; Hiroki Masuda; Ryohei Ohtani; Satoshi Kuwabara
Journal:  J Neurol       Date:  2018-03-12       Impact factor: 4.849

Review 8.  Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.

Authors:  Suradech Suthiphosuwan; David Kim; Aditya Bharatha; Jiwon Oh
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 9.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

10.  Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Authors:  Konstantin Huhn; Antonios Bayas; Sebastian Doerck; Benedikt Frank; Kathrin Gerbershagen; Kerstin Hellwig; Boris Kallmann; Christoph Kleinschnitz; Ingo Kleiter; De-Hyung Lee; Volker Limmroth; Mathias Mäurer; Sven Meuth; Peter Rieckmann; Tobias Ruck; Ralf Gold; Ralf A Linker
Journal:  J Neurol       Date:  2018-04-25       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.